NCT01303536

Ondansetron Augmentation in Treatment-resistant OCD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Institute of Neuroscience, Florence, Italy · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms among obsessive compulsive disorder resistant patients.

Conditions

• Obsessive Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Ondansetron	obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2011-02-24
• Last updated: 2011-02-24

Locations

1 site across 1 country: Italy